Global HPV Vaccines Market Growth 2023-2029

Global HPV Vaccines Market Growth 2023-2029

Human papilloma virus (HPV) vaccines are vaccines that prevent infection by certain types of human papillomavirus. Available vaccines protect against either two, four, or nine types of HPV. All vaccines protect against at least HPV type 16 and 18 that cause the greatest risk of cervical cancer. It is estimated that they may prevent 70% of cervical cancer, 80% of anal cancer, 60% of vaginal cancer, 40% of vulvar cancer, and possibly some mouth cancer. They additionally prevent some genital warts with the vaccines against 4 and 9 HPV types providing greater protection.

LPI (LP Information)' newest research report, the “HPV Vaccines Industry Forecast” looks at past sales and reviews total world HPV Vaccines sales in 2022, providing a comprehensive analysis by region and market sector of projected HPV Vaccines sales for 2023 through 2029. With HPV Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world HPV Vaccines industry.

This Insight Report provides a comprehensive analysis of the global HPV Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on HPV Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global HPV Vaccines market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for HPV Vaccines and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global HPV Vaccines.

The global HPV Vaccines market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

HPV vaccine is an inactivated (not live) vaccine which protects against four major types of HPV. These include two types that cause about 70% of cervical cancer and two types that cause about 90% of genital warts. HPV vaccine can prevent most genital warts and most cases of cervical cancer. Human papillomaviruses (HPVs) are a group of more than 200 related viruses. More than 40 HPV types can be easily spread through direct sexual contact, from the skin and mucous membranes of infected people to the skin and mucous membranes of their partners. They can be spread by vaginal, anal, and oral sex (1). Other HPV types are responsible for non-genital warts, which are not sexually transmitted. The segment of Female HPV vaccine market witnessed growth at a noteworthy rate over the past few years and is expected to grow in the forecast period on the back of rising awareness regarding HPV related fatal diseases, rising healthcare expenditures along with rising disposable incomes. North America and Europe accounts for the maximum market share of the global HPV vaccines market and is expected to grow at highest CAGR during the forecast period.

This report presents a comprehensive overview, market shares, and growth opportunities of HPV Vaccines market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Adolescents
Adults

Segmentation by application
Male
Female

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Astellas Pharma
CSL
Emergent BioSolutions
GlaxoSmithKline
Johnson & Johnson
MedImmune
Merck
Pfizer
Sanofi Pasteur
Serum Institute

Key Questions Addressed in this Report

What is the 10-year outlook for the global HPV Vaccines market?

What factors are driving HPV Vaccines market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do HPV Vaccines market opportunities vary by end market size?

How does HPV Vaccines break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.